Do you inform patients about risks and chances of success associated with different choices when treatment needs to be changed? This approach takes time and requires patient health literacy. Results from a discrete-choice experiment in scleroderma lung disease add to the debate on shared decision-making.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bruni, C. et al. Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment. Rheumatology https://doi.org/10.1093/rheumatology/keac126 (2022).
Aguiar, M. et al. Co-production of randomized clinical trials with patients: a case study in autologous hematopoietic stem cell transplant for patients with scleroderma. Trials 22, 611 (2021).
Kato, M. et al. Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis. Sci. Rep. 9, 12062 (2019).
Fernández-Codina, A., Walker, K. M. & Pope, J. E., Scleroderma Algorithm Group. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol. 70, 1820–1828 (2018).
Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. 79, 685–699 (2020).
Kowal-Bielecka, O. et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann. Rheum. Dis. 76, 1327–1339 (2017).
Fleischmann, R., Jairath, V., Mysler, E., Nicholls, D. & Declerck, P. Nonmedical switching from originators to biosimilars: does the nocebo effect explain treatment failures and adverse events in rheumatology and gastroenterology? Rheumatol. Ther. 7, 35–64 (2020).
The Decision Lab. The paradox of choice https://thedecisionlab.com/reference-guide/economics/the-paradox-of-choice (2022).
Peters, E., Hart, P. S. & Fraenkel, L. Informing patients: the influence of numeracy, framing, and format of side effect information on risk perceptions. Med. Decis. Making. 31, 432–436 (2011).
Harrison, M., Milbers, K., Hudson, M. & Bansback, N. Do patients and health care providers have discordant preferences about which aspects of treatments matter most? Evidence from a systematic review of discrete choice experiments. BMJ Open 7, e014719 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Pope, J.E. To choose or not? The value of discrete-choice experiments in rheumatology. Nat Rev Rheumatol 18, 433–434 (2022). https://doi.org/10.1038/s41584-022-00799-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-022-00799-z